Imaging of Gaucher disease

Area of Science:

• Biochemistry
• Genetics
• Medical Imaging

Background:

• Gaucher disease is a lysosomal storage disorder caused by glucocerebrosidase deficiency.
• This deficiency leads to glucosylceramide accumulation in the reticuloendothelial system, causing hematologic, visceral, and skeletal manifestations.
• Hepatosplenomegaly and anemia are common hematologic and visceral signs.

Purpose of the Study:

• To review the clinical manifestations of Gaucher disease.
• To discuss the role of enzyme replacement therapy (ERT) in managing Gaucher disease.
• To highlight the importance of imaging in diagnosis and monitoring.

Main Methods:

• Review of existing literature on Gaucher disease.
• Discussion of treatment modalities, including ERT and substrate reduction therapy.
• Emphasis on the utility of various imaging techniques (radiography, CT, MRI, radionuclide scanning).

Main Results:

• ERT effectively improves hematologic, visceral, and skeletal manifestations of Gaucher disease.
• Visceral and hematologic symptoms typically respond to ERT within months to years.
• Skeletal manifestations show slower improvement, often requiring several years of treatment.
• Imaging, particularly MRI, is vital for assessing disease burden and treatment response.

Conclusions:

• Enzyme replacement therapy is the established standard of care for Gaucher disease.
• Imaging modalities play a critical role in the diagnosis and ongoing management of patients.
• Newer therapies like substrate reduction are being explored for Gaucher disease treatment.